Hannah Yejin Kim

Hannah Yejin Kim

Auto-generated profile, based on publicly available information

Hannah Yejin Kim

Infectious Diseases Institute (Sydney ID), The University of Sydney , Camperdown, New South Wales , Australia

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2021 in Therapeutic Drug Monitoring
Verified
Journal Article
Open access
AMAnne-Grete Märtson
Anne-Grete Märtson
AEAngela E. Msc Edwina
Angela E. Msc Edwina
HKHannah Yejin Kim
Hannah Yejin Kim
MKMarjolein Knoester
Marjolein Knoester
Daniel Johannes TouwDaniel Johannes Touw
Daniel Johannes Touw
JAJan-Willem C Alffenaar
Jan-Willem C Alffenaar
Background: Ganciclovir is the mainstay of therapy for the prophylaxis and treatment of Cytomegalovirus. However, therapy with this antiviral agent is hindered by side effects such as myelosuppression, which often leads to therapy cessation. Underdosing, as an attempt to prevent side effects, can lead to drug resistance and therapy failure. Therapeutic drug monitoring (TDM) has been used to overcome these problems. The purpose of this narrative review was to give an overview of ganciclovir TDM, available assays, population pharmacokinetic models, and discuss the current knowledge gaps. Methods: For this narrative review, a nonsystematic literature search was performed on the PubMed database in April 2021. The following search terms were used: ganciclovir, valganciclovir, pharmacokinetics, pharmacodynamics, population pharmacokinetics, therapeutic drug monitoring, bioassay, liquid chromatography coupled with tandem mass spectrometry, liquid chromatography, chromatography, spectrophotometry, and toxicity. In addition, the reference lists of the included articles were screened. Results: The most common bioanalysis method identified was liquid chromatography coupled with tandem mass spectrometry. There are different models presenting ganciclovir IC50; however, establishing a pharmacokinetic/pharmacodynamic target for ganciclovir based on preclinical data is difficult because there are no studies combining dynamic drug exposure in relation to inhibition of viral replication. The data on ganciclovir TDM show large interindividual variability, indicating that TDM may play a role in modifying the dose to reduce toxicity and prevent treatment failure related to low concentrations. The main hurdle for implementing TDM is the lack of robust data to define a therapeutic window. Conclusions: Although the pharmacokinetics (PK) involved is relatively well-described, both the pharmacodynamics (PD) and pharmacokinetic/pharmacodynamic relationship are not. This is because the studies conducted to date have mainly focused on estimating ganciclovir exposure, and owing to the limited therapeutic options for CMV infections, future studies on ganciclovir are warranted.

27 June 2024 in Medical Mycology
Verified
Journal Article
Open access
PDF file
CMC Orla Morrissey
C Orla Morrissey
HKHannah Y Kim
Hannah Y Kim
TDTra-My N Duong
Tra-My N Duong
EMEric Moran
Eric Moran
Ana Alastruey-IzquierdoAna Alastruey-Izquierdo
Ana Alastruey-Izquierdo
JBJustin Beardsley
Justin Beardsley
Recognizing the growing global burden of fungal infections, the World Health Organization established a process to develop a priority list of fungal pathogens (FPPL). In this systematic review, we aimed to evaluate the epidemiology and impact of invasive infections caused by Aspergillus fumigatus to inform the first FPPL. The pre-specified criteria of mortality, inpatient care, complications and sequelae, antifungal susceptibility, risk factors, preventability, annual incidence, global distribution, and emergence were used to search for relevant articles between 1 January 2016 and 10 June 2021. Overall, 49 studies were eligible for inclusion. Azole antifungal susceptibility varied according to geographical regions. Voriconazole susceptibility rates of 22.2% were reported from the Netherlands, whereas in Brazil, Korea, India, China, and the UK, voriconazole susceptibility rates were 76%, 94.7%, 96.9%, 98.6%, and 99.7%, respectively. Cross-resistance was common with 85%, 92.8%, and 100% of voriconazole-resistant A. fumigatus isolates also resistant to itraconazole, posaconazole, and isavuconazole, respectively. The incidence of invasive aspergillosis (IA) in patients with acute leukemia was estimated at 5.84/100 patients. Six-week mortality rates in IA cases ranged from 31% to 36%. Azole resistance and hematological malignancy were poor prognostic factors. Twelve-week mortality rates were significantly higher in voriconazole-resistant than in voriconazole-susceptible IA cases (12/22 [54.5%] vs. 27/88 [30.7%]; P = .035), and hematology patients with IA had significantly higher mortality rates compared with solid-malignancy cases who had IA (65/217 [30%] vs. 14/78 [18%]; P = .04). Carefully designed surveillance studies linking laboratory and clinical data are required to better inform future FPPL.

13 March 2023 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
CLCindy Lau
Cindy Lau
DMDeborah Marriott
Deborah Marriott
JBJessica Bui
Jessica Bui
MFMelanie Figtree
Melanie Figtree
MGMichael Gould
Michael Gould
JAJan-Willem C Alffenaar
Jan-Willem C Alffenaar

18 March 2021 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
HKHannah Yejin Kim
Hannah Yejin Kim
EREvelien Ruiter
Evelien Ruiter
EJErwin M Jongedijk
Erwin M Jongedijk
HAHemanth Kumar Ak
Hemanth Kumar Ak
BMBen J Marais
Ben J Marais
JAJan-Willem Alffenaar
Jan-Willem Alffenaar
In TB, therapeutic drug monitoring (TDM) is recommended for linezolid; however, implementation is challenging in endemic settings. Non-invasive saliva sampling using a mobile assay would increase the feasibility of TDM. To validate a linezolid saliva assay using a mobile UV spectrophotometer. The saliva assay was developed using NanoPhotometer NP80® and linezolid concentrations were quantified using second-order derivative spectroscopy. Sample preparation involved liquid–liquid extraction of saliva, using saturated sodium chloride and ethyl acetate at 1:1:3 (v/v/v). The assay was validated for accuracy, precision, selectivity, specificity, carry-over, matrix effect, stability and filters. Acceptance criteria were bias and coefficient of variation (CV) <15% for quality control (QC) samples and <20% for the lower limit of quantification (LLOQ). Linezolid concentrations correlated with the amplitude between 250 and 270 nm on the second-order derivative spectra. The linezolid calibration curve was linear over the range of 3.0 to 25 mg/L (R2 = 0.99) and the LLOQ was 3.0 mg/L. Accuracy and precision were demonstrated with bias of −7.5% to 2.7% and CV ≤5.6%. The assay met the criteria for selectivity, matrix effect, carry-over, stability (tested up to 3 days) and use of filters (0.22 μM Millex®-GV and Millex®-GP). Specificity was tested with potential co-medications. Interferences from pyrazinamide, levofloxacin, moxifloxacin, rifampicin, abacavir, acetaminophen and trimethoprim were noted; however, with minimal clinical implications on linezolid dosing. We validated a UV spectrophotometric assay using non-invasive saliva sampling for linezolid. The next step is to demonstrate clinical feasibility and value to facilitate programmatic implementation of TDM.

27 June 2024 in Medical Mycology
Verified
Journal Article
Open access
PDF file
TMTina Marinelli
Tina Marinelli
HKHannah Yejin Kim
Hannah Yejin Kim
CHCatriona Halliday
Catriona Halliday
KGKatherine Garnham
Katherine Garnham
OBOlivia Bupha-Intr
Olivia Bupha-Intr
CMC Orla Morrissey
C Orla Morrissey
Recognizing the growing global burden of fungal infections, the World Health Organization established a process to develop a priority list of fungal pathogens (FPPL). In this systematic review, we aimed to evaluate the epidemiology and impact of infections caused by Fusarium spp., Scedosporium spp., and Lomentospora prolificans to inform the first FPPL. PubMed and Web of Sciences databases were searched to identify studies published between January 1, 2011 and February 23, 2021, reporting on mortality, complications and sequelae, antifungal susceptibility, preventability, annual incidence, and trends. Overall, 20, 11, and 9 articles were included for Fusarium spp., Scedosporium spp., and L. prolificans, respectively. Mortality rates were high in those with invasive fusariosis, scedosporiosis, and lomentosporiosis (42.9%–66.7%, 42.4%–46.9%, and 50.0%–71.4%, respectively). Antifungal susceptibility data, based on small isolate numbers, showed high minimum inhibitory concentrations (MIC)/minimum effective concentrations for most currently available antifungal agents. The median/mode MIC for itraconazole and isavuconazole were ≥16 mg/l for all three pathogens. Based on limited data, these fungi are emerging. Invasive fusariosis increased from 0.08 cases/100 000 admissions to 0.22 cases/100 000 admissions over the time periods of 2000–2009 and 2010–2015, respectively, and in lung transplant recipients, Scedosporium spp. and L. prolificans were only detected from 2014 onwards. Global surveillance to better delineate antifungal susceptibility, risk factors, sequelae, and outcomes is required.

19 January 2019 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
HKHannah Yejin Kim
Hannah Yejin Kim
JDJanna K. Duong
Janna K. Duong
MGMaria Gonzalez
Maria Gonzalez
GLGeorgina Venetia Long
Georgina Venetia Long
AMAlexander M. Menzies
Alexander M. Menzies
ABAlan V. Boddy
Alan V. Boddy